Year: 2022

  • Conversion of Convertible Security

    ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has converted $200,000 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on…

  • FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients

    ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update on the announcement issued on 10 November 2020, in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a potentially life-threatening auto-immune disease. The US Food & Drug Administration (“FDA”) has…

  • Total Share Capital Notification

    The following replaces the ‘Total Share Capital Notification’ announcement released on 30 September 2020 at 7.01am (BST) under RNS No 5041A. In Section 2 below the reference to “Share Options in whole or part” should have stated 25,640,254 not 15,703,942.   1. Information to be provided for on the basis of Article 15, §1, al.…

  • Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients

    ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces further regulatory and operational progress for the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”) a potentially life-threatening auto-immune disease. Key highlights: The FDA has offered to accept submission for a Type ‘A’ Meeting Request;…

  • Total Share Capital Notification Admission to trading on Euronext Growth Brussels of newly issued ordinary shares

    ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company’s Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting…

  • INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2020

    ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2020 (the “Period”). Key Highlights (including post Period review) Financials Stable financial performance over the Period – Cash balance of £2.7m as at 30…

  • Share Subscription into Incanthera plc (“Incanthera”)

    ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that further to a subscription agreement entered into at the time of Incanthera’s IPO onto AQSE Growth Market* in February 2020, ImmuPharma has now executed its subscription agreement to subscribe £250,000 for 2,631,579 ordinary shares of 2p each at a…

  • Repayment of Convertible Security – Lind Global Macro Fund, LP

    ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, stated in its announcement on 2 September 2020 that following the placing,  both Lind Global Macro Fund, LP (“Lind”) and L1 Capital Global Master Opportunities Fund (“L1”) had the right to require repayment of a portion of their convertible security issued…

  • Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients

    ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update on the announcement issued on 27 July 2020, in respect to the submission to the US Food & Drug Administration (“FDA”) of a SPA for Lupuzor™’s Phase III trial in Lupus patients. In ImmuPharma’s discussions with Avion Pharmaceuticals…

  • Conversion of Convertible Security – Lind Global Macro Fund, LP

    ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that Lind Global Macro Fund, LP has converted $150,000 of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on 11 June 2020. The conversion price is…